期刊文献+

Development and validation of a rapid UPLC/MS method for the simultaneous determination of I3C, DIM, and related metabolites and its application to pharmacokinetics studies

Development and validation of a rapid UPLC/MS method for the simultaneous determination of I3C, DIM, and related metabolites and its application to pharmacokinetics studies
原文传递
导出
摘要 Indole-3-carbinol(I3C) and diindolylmethane(DIM) are naturally derived dietary phytochemicals with promising anti-cancer properties that have been demonstrated both in vitro and in vivo. Using reversed-phase ultra-performance liquid chromatography(UPLC) coupled with mass spectrometry(MS), a rapid, specific, and high throughput method was developed and validated for the quantification and identification of I3 C, DIM, and other I3 C metabolites in plasma. Samples containing I3 C or DIM and the internal standard 4-methoxy indole(IS) were extracted using a liquid-liquid extraction technique. The mean recovery was 96.21% for I3 C and 108.5% for DIM. Separation was achieved using a Waters Acquity UPLC HSS T3, 1.8 μm, 2.1 mm×150 mm column and acetonitrile–water gradient elution. The flow rate was 0.3 m L/min and the run time was 9 min. The limits of detection and quantification for I3 C and DIM were 15 ng/m L and 25 ng/m L, respectively. Calibration curves for I3 C and DIM were linear(r2>0.99) over a concentration range of 0.025–20 μg/m L. Precision, accuracy, and stability analysis fulfilled the CDER guidelines criteria. The method was successfully applied to the determination of the pharmacokinetic parameters of I3 C or DIM after oral, intravenous, or intraperitoneal administration to Sprague Dawley rats. The method described here is superior over existing analytical methods for I3 C and its metabolites in terms of sensitivity, speed, and separation. Indole-3-carbinol (I3C) and d'tindolylmethane (DIM) are naturally derived dietary phytochemicals with promising anti-cancer properties that have been demonstrated both in vitro and in vivo. Using reversed-phase ultra-performance liquid chromatography (UPLC) coupled with mass spectrometry (MS), a rapid, specific, and high throughput method was developed and validated for the quantification and identification of I3C, DIM, and other I3C metabolites in plasma. Samples containing I3C or DIM and the internal standard 4-methoxy indole (IS) were extracted using a liquid-liquid extraction technique. The mean recovery was 96.21% for I3C and 108.5% for DIM. Separation was achieved using a Waters Acquity UPLC HSS T3, 1.8 ~tm, 2.1 mm^150 mm column and acetonitrile-water gradient elution. The flow rate was 0.3 mL/min and the run time was 9 min. The limits of detection and quantification for I3C and DIM were 15 ng/mL and 25 ng/mL, respectively. Calibration curves for I3C and DIM were linear (r2〉0.99) over a concentration range of 0.025-20 p.g/mL. Precision, accuracy, and stability analysis fulfilled the CDER guidelines criteria. The method was successfully applied to the determination of the pharmacokinetic parameters of I3C or DIM after oral, intravenous, or intraperitoneal administration to Sprague Dawley rats. The method described here is superior over existing analytical methods for I3C and its metabolites in terms of sensitivity, speed, and separation.
出处 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2016年第7期477-488,共12页 中国药学(英文版)
基金 R01 CA118947 R01 CA152826 from National Cancer Institute(NCI) R01AT007065 from the National Center for Complementary and Alternative Medicines(NCCAM) the Office of Dietary Supplements(ODS) the National Institute of Health Grant R01 CA073674
关键词 UPLC/MS INDOLE-3-CARBINOL DIINDOLYLMETHANE PHARMACOKINETICS SINGLE-DOSE administration SPRAGUE-DAWLEY Rats UPLC/MS, Indole-3-Carbinol, Diindolylmethane, Pharmacokinetics, Single-dose administration, Sprague-Dawley Rats
  • 相关文献

参考文献22

  • 1Modan, B.; Barrell, B.; Lubin, F.; Modan, M.; Greenberg, R.; Graham, S. J. Natl. Cancer Inst. 1975, 55, 15-18.
  • 2Graham, S. Cancer Res. 1983, 43, 2409s-2413s.
  • 3Cohen, J.; Kristal, A.; Stanford, J. J. Natl. Cancer Inst. 2000, 92, 61-68.
  • 4Tavani, A.; Vecchia, C.L. Am J. Clin. Nutr. 1995, 61, 1374S-1377S.
  • 5Telang, N.; Katdare, M.; Bradlow, H.; Osborne, M.; Fishman, J. Proc. Soc. Exp. Bio. Med. 1997, 216, 246-252.
  • 6Bradfield, C.; Bjeldanes, L. J. Toxicol. Environ. Health. 1987, 21.
  • 7Yuan, F.; Chen, D.; Liu, K.; Sepkovic, D.; Bradlow, H.; K, A. Anticancer Re.s 1999, 19, 1673-1680.
  • 8Wattenberg, L.; Loub, W. Cancer Res. 1978, 38, 1410-1413.
  • 9Bradlow, H.; Michnovicz, J.; Telang, N.; Osborne, M. Carcinogenesis. 1991, 12, 1571-1574.
  • 10Nixon, J.; Hendricks, J.; Pawlowski, N.; Pereira, C.; Sinnhuber, R.; Bailey, G. Carcinogenesis. 1984, 5, 615-619.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部